Safety And Pharmacology Of SNX-5422 Mesylate In Subjects With Refractory Hematological Malignancies

A Phase 1, Open-label, Dose-Escalation Study Of The Safety And Pharmacokinetics Of SNX-5422 Mesylate In Subjects With Refractory Hematological Malignancies

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00595686

Enrollment

Registered

2008-01-16

Start date

2008-01-31

Completion date

2010-05-31

Last updated

2012-05-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hematologic Neoplasms

Keywords

Hematologic Malignancies Hsp90 Hematologic Malignancy

Brief summary

Hsp90 is a chemical in the body that is involved in the promotion of cancer. SNX-5422 is an experimental drug that blocks Hsp90. It is being evaluated for safety and efficacy in patients with cancer.

Interventions

DRUGSNX-5422

dose escalated; tablets every other day; undetermined duration until disease progression

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* \>18 years old * Karnofsky performance status \> 60 * confirmed hematological malignancy * refractory to available therapy or for which no therapy is available * adequate hepatic, renal and hematological function

Exclusion criteria

* CNS malignancy * at risk for prolonged QT interval * significant GI/liver disease * other serious concurrent illness or medical condition

Design outcomes

Primary

Measure	Time frame
adverse events and other safety assessments	continuous

Secondary

Measure	Time frame
disease response specific to the hematological malignancy	after every 2 cycles

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026